Drug metabolism and personalized therapy is switching its publication model to open access

The new year of 2026 marks the beginning of a new chapter for the journal Drug Metabolism and Personalized Therapy. In cooperation with the editors, the publisher will convert the journal to Diamond Open Access in accordance with the Subscribe to Open (S2O) model, on a year-by-year basis.

Starting in 2026, all articles will immediately appear under the Creative Commons license CC-BY at no publication costs for the authors. The open access transformation is based on an alternative, sustainable, and equitable approach to transitioning subscription-based journals one year at a time, through the continuation of existing subscriptions. The prerequisite for successful transformation is that subscriptions are continued to the same extent as before. The editors of the Drug Metabolism and Personalized Therapy and the publisher De Gruyter Brill would, therefore, like to thank all subscribers for their support.

The proportion of open access publications in the fields of pharmacogenetics and pharmacogenomics, biochemical pharmacology, drug metabolizing enzymes, molecular and clinical pathology and pharmacokinetics, drug-drug interactions, herbal and traditional medicine has increased significantly in recent years, and in several countries and regions it has almost become the standard, not least because funders and institutions are imposing open research requirements. Above all, we are aware of the enormous social need to make rational, accurate information available to everyone and thus promoting scientific developments as best as possible.

With S2O, we aim to eliminate barriers not only at the end of the authors, who may not have the means to cover Article Processing Charges (APCs), but also for our readers. Open access increases visibility, reach, and overall impact of the published research.

You can easily support the S20 model of Drug Metabolism and Personalized Therapy by renewing your existing subscription in the usual way or reaching out to your librarian and recommend a subscription for 2025. Please refer to the S2O Subscribe to Open | De Gruyter Brill.

Further readings

1. Subscribe to Open Community of Practice

2. C. Brundy & G. Steel: Subscribe to progress. Advancing equity through openness. Commonplace. 2021

3. Crow, R., Gallagher, R. and Naim, K. (2020), Subscribe to Open: A practical approach for converting subscription journals to open access, Learned Publishing, 33: 181–185.

On behalf of the Publisher and the Editorial Board of the journal Drug Metabolism and Personalized Therapy,